查看“欣普尼”的源代码

<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;">

    <div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;">
        <p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;">
            <strong>[[欣普尼]]</strong>（<strong>[[Simponi]]</strong>，通用名：<strong>[[戈利木单抗]]</strong>）是全球首个获批的每月一次[[皮下注射]]的全人源化抗<strong>[[肿瘤坏死因子α]]</strong>（<strong>[[TNF-α]]</strong>）单克隆抗体。该药物由[[强生]]旗下[[杨森]]（[[Janssen]]）公司开发，通过转基因小鼠技术制备而成。相比于早期的[[TNF抑制剂]]，[[欣普尼]]具有更高的亲和力和稳定性，能有效阻断[[TNF-α]]与受体的结合，从而抑制<strong>[[炎症级联反应]]</strong>。临床上，它被广泛用于治疗<strong>[[强直性脊柱炎]]</strong>、<strong>[[类风湿关节炎]]</strong>、<strong>[[银屑病关节炎]]</strong>及[[溃疡性结肠炎]]，其便捷的给药方式极大地改善了慢性[[自身免疫性疾病]]患者的长程管理体验。
        </p>
    </div>

    <div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; float: right; margin: 0 0 25px 25px; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;">
        
        <div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #ffffff 0%, #e0f2fe 100%); text-align: center; cursor: pointer;">
            <div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">[[欣普尼]]</div>
            <div style="font-size: 0.75em; opacity: 0.85; margin-top: 4px;">[[Simponi]] / [[戈利木单抗]] · 点击展开</div>
        </div>
        
        <div class="mw-collapsible-content">
            <div style="padding: 20px; text-align: center; background-color: #f8fafc;">
                <div style="padding: 12px; border: 1px solid #e2e8f0; border-radius: 8px; background: #fff; display: inline-block;">
                    <div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">[[欣普尼]]抗体分子空间结构示意</div>
                </div>
                <div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心靶点：[[TNF-α]] (TNFSF2)</div>
            </div>

            <table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;">
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 45%;">药物类型</th>
                    <td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">[[全人源单克隆抗体]]</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">亚型</th>
                    <td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[IgG1]]κ</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">给药频率</th>
                    <td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">28天一次 (Q4W)</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子量</th>
                    <td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">约 150 kDa</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">研发商</th>
                    <td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[杨森]] (Janssen)</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569;">CAS号</th>
                    <td style="padding: 12px; color: #0f172a;">476181-74-5</td>
                </tr>
            </table>
        </div>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：全人源化的精准中和</h2>
    
    <p style="margin: 15px 0; text-align: justify;">
        [[欣普尼]]通过精准识别并结合[[TNF-α]]分子，切断炎症风暴的源头：
    </p>
    [Image showing Simponi antibody neutralizing soluble and membrane-bound TNF-alpha]
    <ul style="padding-left: 25px; color: #334155;">
        <li style="margin-bottom: 12px;"><strong>双重中和作用：</strong>[[欣普尼]]能同时结合可溶型及膜结合型[[TNF-α]]。通过阻断其与受体[[TNFR1]]及[[TNFR2]]的结合，迅速抑制下游<strong>[[NF-κB]]</strong>和<strong>[[p38 MAPK]]</strong>等致炎通路。</li>
        <li style="margin-bottom: 12px;"><strong>低免疫原性：</strong>作为[[全人源单克隆抗体]]，其氨基酸序列完全来源于人类基因，相比[[英夫利昔单抗]]（嵌合抗体）或[[阿达木单抗]]，产生[[抗药物抗体]]（[[ADA]]）的风险更低，长期使用的疗效更为稳定。</li>
        <li style="margin-bottom: 12px;"><strong>药效学优势：</strong>具有极高的靶向亲和力（$K_{D}$值极低），能更持久地停留在作用靶点，这也是其支持每月给药一次的分子基础。</li>
    </ul>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床评价矩阵：欣普尼核心研究</h2>

    <div style="overflow-x: auto; margin: 25px auto; width: 95%;">
        <table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;">
            <tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;">
                <th style="padding: 10px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">研究代号</th>
                <th style="padding: 10px; border: 1px solid #cbd5e1; color: #475569;">受试人群</th>
                <th style="padding: 10px; border: 1px solid #cbd5e1; color: #1e40af;">临床意义</th>
            </tr>
            <tr>
                <td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[GO-RAISE]]</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">[[强直性脊柱炎]]</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">显著改善腰椎活动度及 [[ASAS20/40]] 缓解率，延缓影像学进展。</td>
            </tr>
            <tr>
                <td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[GO-FORWARD]]</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">[[类风湿关节炎]]</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">针对[[甲氨蝶呤]]反应不佳患者，联合给药大幅提升 [[ACR50]]。</td>
            </tr>
            <tr>
                <td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[PURSUIT研究]]</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">[[溃疡性结肠炎]]</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">诱导并维持肠道黏膜愈合，降低临床失效率。</td>
            </tr>
        </table>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">诊疗策略：规范化使用与风险拦截</h2>
    <p style="margin: 15px 0; text-align: justify;">
        [[欣普尼]]的应用需结合精密的临床监测，重点在于平衡抗炎深度与免疫风险：
    </p>
    <ul style="padding-left: 25px; color: #334155;">
        <li style="margin-bottom: 12px;"><strong>安全筛查前置：</strong>应用前必须进行<strong>[[结核分枝杆菌]]</strong>（[[T-SPOT]]）和<strong>[[乙肝]]</strong>（[[HBV]]）筛查。[[TNF抑制剂]]可能导致潜伏性结核复燃。</li>
        <li style="margin-bottom: 12px;"><strong>便捷化给药：</strong>采用智能注射笔（[[Variact]]），患者可在家中自行皮下给药。每月固定日期给药有助于维持稳定的血药谷浓度。</li>
        <li style="margin-bottom: 12px;"><strong>长期安全性监测：</strong>需关注注射部位反应、上呼吸道感染及潜在的[[淋巴瘤]]风险。对于有[[充血性心力衰竭]]病史的患者应慎用。</li>
        <li style="margin-bottom: 12px;"><strong>[[治疗药物监测]] (TDM)：</strong>若出现药效减退，应检测血清药物浓度及[[ADA]]，以指导剂量调整或更换生物制剂。</li>
    </ul>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2>
    <div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;">
        <ul style="margin: 0; padding-left: 20px; color: #334155;">
            <li style="margin-bottom: 8px;"><strong>[[TNF-α]]：</strong>由[[巨噬细胞]]产生的核心致炎细胞因子，是多种自免疾病的“指挥官”。</li>
            <li style="margin-bottom: 8px;"><strong>[[全人源化抗体]]：</strong>完全采用人源基因序列，旨在将机体抗体中和风险降至最低。</li>
            <li style="margin-bottom: 8px;"><strong>[[中和抗体]] (ADA)：</strong>针对生物制剂产生的抗体，常导致继发性失效。</li>
            <li style="margin-bottom: 8px;"><strong>[[生物类似药]]：</strong>随着原研药专利到期，[[欣普尼]]的类似药研发已成为全球热点。</li>
        </ul>
    </div>

    <div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;">
        <span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span>
        
        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [1] <strong>Smolen JS, et al. (2009).</strong> <em>Golimumab in patients with active rheumatoid arthritis: results of the GO-FORWARD study.</em> <strong>[[Annals of the Rheumatic Diseases]]</strong>.[Academic Review]<br>
            <span style="color: #475569;">[权威点评]：该研究确立了欣普尼在类风湿关节炎联合治疗中的长期疗效优势。</span>
        </p>

        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [2] <strong>Inman RD, et al. (2008).</strong> <em>Efficacy and safety of golimumab in patients with active ankylosing spondylitis.</em> <strong>[[Arthritis & Rheumatism]]</strong>.<br>
            <span style="color: #475569;">[核心价值]：首次在大型RCT试验中证实了每月一次给药模式在强直性脊柱炎中的可行性。</span>
        </p>
    </div>

    <div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;">
        <div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;">
            [[欣普尼]] (Simponi) 诊疗生态 · 知识图谱
        </div>
        <table style="width: 100%; border-collapse: collapse; background-color: #ffffff;">
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td>
                <td style="padding: 10px 15px; color: #334155;">[[TNF-α]]•[[TNFR1]]•[[TNFR2]]•[[NF-κB]]•[[CRP]]</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">竞争/同类</td>
                <td style="padding: 10px 15px; color: #334155;">[[阿达木单抗]]•[[依那西普]]•[[英夫利昔单抗]]•[[托法替布]](JAK抑制剂)</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略实体</td>
                <td style="padding: 10px 15px; color: #334155;">[[杨森]]•[[强生]]•[[FDA]]•[[NMPA]]•[[EULAR]]</td>
            </tr>
            <tr>
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">前沿研究</td>
                <td style="padding: 10px 15px; color: #334155;">[[针对葡萄膜炎的探索]]•[[欣普尼静脉滴注剂型的应用]]•[[减量维持治疗的共识研究]]</td>
            </tr>
        </table>
    </div>

</div>